187,707 research outputs found
muhamanz/Secreto-Oral-Metagenomics: Secreto-Oral-Metagenomics
No full text<p>Source code for the article Multi-kingdom oral microbiome interactions in early-onset cryptogenic ischemic stroke
Muhammed Manzoor<em>, Jaakko Leskelä, Milla Pietiäinen, Nicolas Martinez-Majander, Pauli Ylikotila4, Eija Könönen, Teemu Niiranen, Leo Lahti, Juha Sinisalo, Jukka Putaala, Pirkko J. Pussinen</em>†, Susanna Paju*†</p>
<h2>What's Changed</h2>
<ul>
<li>license added by @antagomir in https://github.com/muhamanz/Secreto-Oral-Metagenomics/pull/1</li>
</ul>
<h2>New Contributors</h2>
<ul>
<li>@antagomir made their first contribution in https://github.com/muhamanz/Secreto-Oral-Metagenomics/pull/1</li>
</ul>
<p><strong>Full Changelog</strong>: https://github.com/muhamanz/Secreto-Oral-Metagenomics/commits/Secreto-Oral-Metagenomics</p>
El secreto como estrategia dramática: el caso de "Nadie fíe su secreto", de Calderón
No full textA pesar de que la crítica ha puesto de manifiesto la relevancia del tema del secreto en la producción calderoniana, no todas sus manifestaciones han sido atendidas. Este trabajo estudia la construcción dramática del secreto de amor en la comedia Nadie fíe su secreto (c. 1629) desde una doble perspectiva: temática y retórica. Con raíces en la tradición clásica, el secreto amoroso como motor de la acción parte de la contención de lo oculto para desembocar en su revelación pública. Esta expresión temática debe ser entendida en relación con los recursos retóricos del secreto, tan vinculados al silencio, puesto que potencian la intriga.Despite the fact that secrecy has been highlighted as an outstanding theme in Calde-rón’s writing, it has not been studied on every occasion. This paper aims to analyze its dramatic construction in the comedia Nadie fíe su secreto (c. 1629) from a thematic and rhetorical perspective. This main theme is traced back to the classical tradition and is studied from the development of the plot: the secret of love contention ends with its public revelation. This particular construction of secrecy is deeply connected to the rhetorical resources, especially to those related to the expression of silence, which strengthen the suspense
Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer
No full textNoemí M. Girbal-Blacha; Sonia Mendonça (coord.) 2007. Cuestiones agrarias en Argentina y Brasil . Buenos Aires: Prometeo. 380 p
No full textFil: Secreto, María Verónica. Universidade Federal Fluminense; CPDA/Universidade Federal Rural do Rio De Janeiro
Medical ovariectomy in menopausal breast cancer patients with high testosterone levels : a further step toward tailored therapy
No full textFive years of adjuvant therapy with anti-estrogens reduce the incidence of disease progression by about 50% in estrogen receptor-positive breast cancer patients, but late relapse can still occur after anti-estrogens have been discontinued. In these patients, excessive androgen production may account for renewed excessive estrogen formation and increased risks of late relapse. In the 50% of patients who do not benefit with anti-estrogens, the effect of therapy is limited by de novo or acquired resistance to treatment. Androgen receptor and epidermal growth factor receptor overexpression are recognized mechanisms of endocrine resistance suggesting the involvement of androgens as activators of the androgen receptor pathway and as stimulators of epidermal growth factor synthesis and function. Data from a series of prospective studies on operable breast cancer patients, showing high serum testosterone levels are associated to increased risk of recurrence, provide further support to a role for androgens in breast cancer progression. According to the above reported evidence, we proposed to counteract excessive androgen production in the adjuvant setting of estrogen receptor-positive patients and suggested selecting postmenopausal patients with elevated levels of serum testosterone, marker of ovarian hyperandrogenemia, for adjuvant treatment with a gonadotropins-releasing hormone analogue (medical oophorectomy) in addition to standard therapy with anti-estrogens. The proposed approach provides an attempt of personalized medicine that needs to be further investigated in clinical trials
Un secreto insondable. Subjetividad y literatura
No full textMe propongo hablar del secreto como raíz y dinámica de dos figuras inevitables: la subjetividad y la literatura en un horizonte posmetafísico, un horizonte que rompe la solidez de lo real y del fundamento y nos devuelve a la fluidificación propia de la libertad incondicionada: la pérdida de las raíces, el desligarse de todo fundamento último. La única y última autoridad no es sino el sí mismo. Todos nos convertimos en autores: la máxima autoridad, el principio legitimador, la última instancia y la última palabra de nuestra existencia. Y la máxima autoría: a nosotros y a nadie más atañe nuestra constitución. Tal creación se vuelve un desafío insalvable, inevitable, ineludible
El valor del secreto
No full textNecesidad del secreto de Estado: fundamento y límites. 20 aniversario de las leyes fundacionales del CNI
Urinary testosterone as a marker of risk of recurrence in operable breast cancer
No full textWe investigated the role of urinary testosterone levels as a marker of risk of recurrent disease in 113 operable breast cancer patients (70 premenopausal, 43 postmenopausal). Twenty-four-hour urine collections for testosterone measurement were obtained before surgical treatment, between 20-40 days thereafter, and then every 6 months for 5 years. The cutoff values to separate 'high testosterone (A+)' from 'normal testosterone (A-)' were 8.0 micrograms/24 h in premenopause and 4.9 micrograms/24 h in postmenopause. Urinary testosterone levels were considered high when they exceeded the cutoff value in at least 2 of the first 3 measurements (pretreatment, post-treatment, 6 months) of each patient. According to the aforementioned criterion, 33 patients (29.2%) had high testosterone levels, which were associated to axillary node involvement in 16 patients. Thirteen of the latter relapsed during the 5-year follow-up period (5/7 in premenopause, 8/9 in postmenopause). Relapse-free survival (RFS) curves were drawn only for node-positive patients owning to the small number of recurrences observed in the node-negative group. In premenopausal node-positive patients, RFS was significantly different for patients presenting high and normal urinary testosterone levels (77% vs 28%, respectively; logrank test, p < 0.006). In postmenopausal node-positive patients, RFS was also different between the two groups (54% vs 11% in 'high' and 'normal' excretors, respectively) but the difference was not statistically significant. The present findings suggest that urinary testosterone is a prognostic indicator of early breast cancer recurrence in node-positive patients
Testosterone levels as a marker of prognosis to goserelin treatment in metastatic breast cancer
No full textTestosterone levels were measured in blood and urine of 35 premenopausal metastatic breast cancer patients before starting therapy with the gonadotrophin-releasing hormone (GnRH) analogue, goserelin. The aim of the study was to verify the reliability of testosterone measurement as a marker of prognosis. The time interval between starting therapy and progressive disease (time to progression) was chosen to assess prognosis. Univariate and multivariate analysis showed that only urinary testosterone levels were significantly associated with time to progression (Wald test 6.66, P = 0.01 for univariate and Wald test 7.93, P = 0.0049 for multivariate analysis), whereas no association was found for testosterone in blood. A statistical model is proposed to evaluate probability of progressive disease in relation to testosterone values in urine at different times. According to the model, the probability of progression decreases with increasing urinary testosterone values
El secreto médico
No full textEs materia de este trabajo considerar el delicado problema del secreto médico, tanto en su aspecto doctrinario, como institución de derecho, cuanto en el positivo, es decir los elementos que lo configuran y las sanciones que acarrea su violación.Doctor en JurisprudenciaCuenc
- …
